Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ArcticZymes Technologies ASA has a Cash Ratio of 15.20. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for ArcticZymes Technologies ASA's Cash Ratio or its related term are showing as below:
LTS:0DRV'
s Cash Ratio Range Over the Past 10 Years
Min: 1.53 Med: 8.48 Max: 15.61
Current: 15.2
During the past 13 years, ArcticZymes Technologies ASA's highest Cash Ratio was 15.61. The lowest was 1.53. And the median was 8.48.
LTS:0DRV's Cash Ratio is ranked better than 89% of 1318
companies
in the Biotechnology industry
Industry Median: 3.015
vs LTS:0DRV: 15.20
ArcticZymes Technologies ASA (LTS:0DRV) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ArcticZymes Technologies ASA Cash Ratio Related Terms
ArcticZymes Technologies ASA Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (LTS:0DRV) has a Cash Ratio of 15.20 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ArcticZymes Technologies ASA and its competitors. This is 79% above median its historical median of 8.48. Over the past decade, ArcticZymes Technologies ASA's Cash Ratio has ranged from 1.53 to 15.61. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #145 out of 1318 companies in the Biotechnology industry, placing it in the top 11%.
Is ArcticZymes Technologies ASA's Cash Ratio too high?
ArcticZymes Technologies ASA's current Cash Ratio of 15.20 is 79% above median its 10-year median of 8.48. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 15.61. The Biotechnology industry median Cash Ratio is 3.02. ArcticZymes Technologies ASA's value of 15.20 is 404.1% above this industry median. Based on the distribution chart, ArcticZymes Technologies ASA ranks #145 out of 1318 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #145 out of 1318 companies for Cash Ratio. This places ArcticZymes Technologies ASA in the top 11% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 3.02. ArcticZymes Technologies ASA's value of 15.20 is 404.1% above this benchmark. Historically, ArcticZymes Technologies ASA's own Cash Ratio has ranged from 1.53 to 15.61 over the past decade. While the company's 10-year median is 8.48 vs. the industry median of 3.02, ArcticZymes Technologies ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.02, based on 1,318 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArcticZymes Technologies ASA's current Cash Ratio of 15.20 is 404.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ArcticZymes Technologies ASA and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current Cash Ratio is 15.20, which is 79% above median its own 10-year median of 8.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.06, compared to a current price of kr20.80 — trading 17% below its estimated fair value. The current Cash Ratio is 15.20, which is 79% above median its 10-year median of 8.48 and 404.1% above the Biotechnology industry median of 3.02. ArcticZymes Technologies ASA's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current Cash Ratio is 15.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr20.80 is trading 17% below its estimated GF Value™ of kr25.06.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
Cash Ratio: 15.20 (79% above median its 10-year median of 8.48)
GF Value™: kr25.06 vs. price of kr20.80 (17% below fair value)
Industry Position: 404.1% above the Biotechnology median (#145 of 1318)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
72GF Score
Get the complete analysis for LTS:0DRV
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
